CD123 targeted immunotherapy

The present disclosure provides improved CD123 targeting polypeptides and compositions for adoptive T cell therapy for treating, preventing or ameliorating at least one symptom of cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or a condition associated th...

Full description

Saved in:
Bibliographic Details
Main Authors HOLENZ, ANDREW, TIMMER JOHN C, LEUNG WAI-HANG, JARROUR, JORDAN, CRAGO WILLIAM, MACEDO CHELSEA, JONES KYLE, MA MILTON, ECKELMAN, BRENDAN, P, POGSON, MARK
Format Patent
LanguageChinese
English
Published 26.04.2022
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The present disclosure provides improved CD123 targeting polypeptides and compositions for adoptive T cell therapy for treating, preventing or ameliorating at least one symptom of cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or a condition associated therewith. 本公开提供了用于过继性T细胞疗法的改进的CD123靶向多肽和组合物，用于治疗、预防或改善癌症、传染病、自身免疫性疾病、炎性疾病和免疫缺陷的至少一种症状或与其相关的病状。
Bibliography:Application Number: CN202080048002